Drugs / Plasma

Trials 14 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 26 trials
Phase 2 NCT07094724 Jul → Nov 2025 overdue West Nile fever Gili Regev-Yochay MD Recruiting No outcome recorded
Phase 2 NCT04723589 Apr 2021 COVID-19 University of Alabama at Birmingham Withdrawn No outcome recorded
Phase 2 NCT04332380 May → Jul 2020 Coronaviridae infectious disease Universidad del Rosario Completed No outcome recorded
Phase 2 NCT04358783 Apr 2020 → May 2021 COVID-19 Hospital Universitario Dr. Jose E. Gonzalez Completed No outcome recorded
Phase 2 NCT03366220 Mar 2018 → Sep 2019 infectious disease with sepsis The University of Texas Health Science Center, Houston Terminated No outcome recorded
Phase 2 NCT03138317 Jan 2017 → May 2018 osteoarthritis, knee University of Sao Paulo Unknown No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT04332835 Aug → Oct 2020 COVID-19 Universidad del Rosario Completed No outcome recorded
Phase 35 trials
Phase 3 NCT07212998 Aug 2026 → Aug 2029 expected Jason Sperry Not yet recruiting No outcome recorded
Phase 3 NCT06070350 Nov 2024 → Jun 2028 expected Philip Spinella Recruiting No outcome recorded
Phase 3 NCT05638581 Jul 2023 → Dec 2026 expected University of Alabama at Birmingham Recruiting No outcome recorded
Phase 3 NCT05634109 Jan 2023 → Dec 2025 overdue Fundacion Clinica Valle del Lili Recruiting No outcome recorded
Phase 3 NCT01818427 May 2014 → Sep 2017 Jason Sperry Completed No outcome recorded
Phase 42 trials
Phase 4 NCT02774317 Oct 2017 → Jun 2020 blood coagulation disease University of Chicago Withdrawn No outcome recorded
Phase 4 NCT01509274 Aug 2011 → Jun 2012 plantar fasciitis Kolding Sygehus Unknown No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT03981484 Comparator Jan 2020 → Oct 2022 blood coagulation disease, hemorrhagic disease Bellal A. Joseph, MD, FACS Unknown No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT02303964 Comparator Nov 2014 → Jan 2016 Virginia Commonwealth University Withdrawn No outcome recorded
Phase 31 trial
Phase 3 NCT04704869 Background Jan 2017 → Dec 2021 Bryan Cotton Completed No outcome recorded
Phase not applicable1 trial
NCT06495294 Comparator Dec 2024 → Dec 2026 expected Unity Health Toronto Recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

FieldValueCited text
Known as Plasma “Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.” NCT05638581
16

“the participant will receive 3 red blood cell units, 3 fresh frozen plasma units, and half of a platelets apheresis, equivalent to 3 platelets units.” NCT05634109

“Component Therapy (CT) will be RBCs, plasma and platelet units in a 1:1:1 unit ratio.” NCT06070350

NCT04358783

NCT03138317

NCT01509274

NCT03366220

NCT04704869

NCT07094724

NCT01818427

NCT06495294

NCT02303964

NCT07212998

NCT02774317

NCT04332380

NCT03981484

NCT04332835

Known as FFP FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)” NCT02774317
Known as FP24 “FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)” NCT02774317
Known as Thawed plasma ClinicalTrials.gov intervention name — accepted as the source's own label NCT04723589
Modality Other / unclassified “Biological: Transfusion of blood products” NCT05634109
Route Other “3 ml plasma injected once into the plantar fascia” NCT01509274